medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Número 3

<< Anterior Siguiente >>

Ann Hepatol 2011; 10 (3)


Diagnostic significance of plasma osteopontin in hepatitis C virus-related hepatocellular carcinoma

El Makarem MAA, Abdel-Aleem A, Ali A, Saber R, Shatat M, Rahem DA, Sayed D

Idioma: Ingles.
Referencias bibliográficas: 43
Paginas: 296-305
Archivo PDF: 77.29 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Ferlay J, Bray F, Pisani P. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC Press; Lyon: 2004. IARC CancerBase No. 5. version 2.0.

  2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004; 127: S27-S34.

  3. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002; 155: 323-31.

  4. Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003; 38: 493-502.

  5. Bosch FX, Ribes J, Cleries R, Díaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211.

  6. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology 2004; 127: S17-S26.

  7. El-Zayadi AR, Badran HM, Barakat EM, Attia Mel-D, Shawky S, Mohamed MK, Selim O, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol 2005; 11: 5193-8.

  8. Hassan MM, Zaghloul AS, El-Serag HB, Soliman O, Patt YZ, Chappell CL, Beasley RP, et al. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol 2001; 33: 123-6.

  9. Freedman LS, Edwards BK, Ries LAG, eds. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the middle east cancer consortium (MECC) compared with US SEER. National Cancer Institute. Bethesda, MD: NIH Pub. No. 06-5873, 2006.

  10. National Cancer Registry of Egypt. Magnitude of hepatocellular carcinoma in Egypt. Available at: http:// www.nci.edu.eg. Accessed 6 August 2010.

  11. Egyptian Ministry of Health. Egyptian Ministry of Health Annual Report: 2007. Available at: http://www.mohp.gov. eg/Main.asp (accessed 6 July 2010).

  12. Abdel-Aziz F, Habib M, Mohamed MK, Abdel-Hamid M, Gamil F, Madkour S, Mikhail NN, et al. Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology 2000; 32: 111-15.

  13. Khattab MA, Eslam M, Sharwae MA, Hamdy L. Seroprevalence of hepatitis C and B among blood donors in Egypt: Minya Governorate, 2000-2008. Am J Infect Control 2010; 38(8): 640-1.

  14. Lehman EM, Wilson ML. Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systematic review and meta-analysis. Int J Cancer 2009; 124(3): 690-7.

  15. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.

  16. Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, et al; HALT-C Trial Group. Desgamma- carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology 2010; 138(2): 493-502.

  17. Taketa K. a-Fetoprotein: Re-evaluation in hepatology. Hepatology 1990; 12: 1420-32.

  18. Colli A, Fraquelli M, Conte D. Alpha-fetoprotein and hepatocellular carcinoma. Am J Gastroenterol 2006; 101: 1939. Author reply 1940-1.

  19. Gupta S, Bent S, Kohlwes J. Test characteristics of alphafetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med 2003; 139: 46-50.

  20. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007; 43(6): 979-92.

  21. Sherman M. Alpha fetoprotein: An obituary. J Hepatol 2001; 34: 603-5.

  22. Shevde LA, Das S, Clark DW, Samant RS. Osteopontin: an effector and an effect of tumor metastasis. Curr Mol Med 2010; 10(1): 71-81.

  23. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, et al. Overexpression of OPN is related with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 2003; 98: 119-27.

  24. Ye QH, Qin LX, Forgues M, He P, Kim JW, Peng AC, Simon R, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003; 9: 416-23.

  25. El-Din Bessa SS, Elwan NM, Suliman GA, El-Shourbagy SH. Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma. Arch Med Res 2010; 41: 541-7.

  26. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, et al; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.

  27. Zekri AR, El-Din HM, Bahnassy AA, El-Shehabi AM, El-Leethy H, Omar A, Khaled HM. TRUGENE sequencing versus INNOLiPA for sub-genotyping of HCV genotype-4. J Med Virol 2005; 75: 412-20.

  28. Mendy M, Walton R. Molecular pathogenesis and early detection of hepatocellular carcinoma-perspectives from West Africa. Cancer Lett 2009; 286(1): 44-51.

  29. Wang X, Chao L, Ma G, Chen L, Tian B, Zang Y, Sun J. Increased expression of osteopontin in patients with triple- negative breast cancer. Eur J Clin Invest 2008; 38: 438-46.

  30. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, et al. Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 2005; 11: 4646-52.

  31. Celetti A, Testa D, Staibano S, Merolla F, Guarino V, Castellone MD, Iovine R, et al. Overexpression of the cytokine osteopontin identifies aggressive laryngeal squamous cell carcinomas and enhances carcinoma cell proliferation and invasiveness. Clin Cancer Res 2005; 11: 8019-27.

  32. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, Yeatman TJ. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004; 10: 184-90. [PMID: 14734468].

  33. Kim J, Ki SS, Lee SD, Kim YC, Park SH, Cho SY, Hong YJ, et al. Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. Am J Gastroenterol 2006; 101(9): 2051-9.

  34. Soresi M, Magliarisi C, Campagna P, Leto G, Bonfissuto G, Riili A, Carroccio A, et al. Usefulness of a-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res 2003; 23: 1747-53.

  35. Johnson PJ. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 145-59.

  36. Chen RX, Xia YH, Cui JF, Xue TC, Ye SL. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection. J Gastroenterol Hepatol 2010; 25(8): 1435-42.

  37. Xie H, Song J, Du R, Xue TC, Ye SL. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis 2007; 39(2): 167-72.

  38. Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, et al. Serum alphafetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001; 34(4): 570-5.

  39. Gambarin-Gelwan M, Wolf DC, Shapiro R, Schwartz ME, Min AD. Sensitivity of commonly available screening tests in detecting hepatocellular carcinoma in cirrhotic patients undergoing liver transplantation. Am J Gastroenterol 2000; 95(6): 1535-8.

  40. Singh RP, Patarca R, Schwartz J, Singh P, Cantor H. Definition of a specific interaction between the early T lymphocyte activation 1 (Eta-1) protein and murine macrophages in vitro and its effect upon macrophages in vivo. J Exp Med 1990; 171: 1931-42.

  41. Ashkar S,Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, Rittling SR, et al. Eta-1 (osteopon tin): An early component of type-1 (cell-mediated) immunity. Science 2000; 287: 860-4.

  42. Ramaiah SK, Rittling S. Role of osteopontin in regulating hepatic inflammatory responses and toxic liver injury. Expert Opin Drug Metab Toxicol 2007; 3: 519-26.

  43. Zhang H, Ye QH, Ren N, Zhao L, Wang YF, Wu X, Sun HC, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132(11): 709-17.




2020     |     www.medigraphic.com